3 Stock-Split Stocks With 51 percent to 128 percent Upside in 2024, According to Select Wall Street Analysts - The Motley Fool
| CMOTEC-B | SEK 1.58 0.08 4.82% |
About 61% of Scandinavian ChemoTech's investor base is looking to short. The analysis of current outlook of investing in Scandinavian ChemoTech AB suggests that many traders are alarmed regarding Scandinavian ChemoTech's prospects. The current market sentiment, together with Scandinavian ChemoTech's historical and current headlines, can help investors time the market. In addition, many technical investors use Scandinavian ChemoTech stock news signals to limit their universe of possible portfolio assets.
Scandinavian |
3 Stock-Split Stocks With 51 percent to 128 percent Upside in 2024, According to Select Wall Street Analysts The Motley Fool
Read at news.google.com
 |
Scandinavian ChemoTech Fundamental Analysis
We analyze Scandinavian ChemoTech's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Scandinavian ChemoTech using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Scandinavian ChemoTech based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Net Asset
Net Asset Comparative Analysis
Scandinavian ChemoTech is currently under evaluation in net asset category among its peers. Net Asset is the current market value of a fund less its liabilities. In a nutshell, if the fund is liquidated or all of the assets is sold out, the net asset will be the amount that the shareholders would demand back from the fund.
Scandinavian ChemoTech Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Scandinavian ChemoTech stock to make a market-neutral strategy. Peer analysis of Scandinavian ChemoTech could also be used in its relative valuation, which is a method of valuing Scandinavian ChemoTech by comparing valuation metrics with similar companies.
Peers
Scandinavian ChemoTech Related Equities
| ERMA | Enorama Pharma | 7.28 | ||||
| ALZ | Alzinova | 2.45 | ||||
| CANTA | Cantargia | 1.18 | ||||
| XINT | Xintela AB | 2.50 | ||||
| VICO | Vicore Pharma | 5.84 |
Complementary Tools for Scandinavian Stock analysis
When running Scandinavian ChemoTech's price analysis, check to measure Scandinavian ChemoTech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Scandinavian ChemoTech is operating at the current time. Most of Scandinavian ChemoTech's value examination focuses on studying past and present price action to predict the probability of Scandinavian ChemoTech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Scandinavian ChemoTech's price. Additionally, you may evaluate how the addition of Scandinavian ChemoTech to your portfolios can decrease your overall portfolio volatility.
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account |